FRIDAY, JULY 21, 2017

NIAID supports clinical research for HIV, other infectious diseases

The Division of AIDS (DIAIDS), a branch of the National Institute of Allergy and Infectious Diseases (NIAID), supports the clinical research for therapies designed to treat HIV infections and similar infectious diseases. Read More »

New computer model estimates benefits of HIV care

Researchers from Johns Hopkins recently developed a new computer model that could save lives and dollars. Read More »

New technology for diagnosing Ebola

Rapid Ebola detection tool creates automated lab on a single chip. Read More »

Variations in malaria vaccine's effectiveness are under review

The National Institute of Allergy and Infectious Diseases (NIAID), a branch of the National Institutes of Health (NIH), recently funded a study that shows why malaria vaccines only partially protect infants and children from the virus. Read More »

Immune responses offer new information for HIV vaccine development

Recent studies have shown that new information concerning immune responses may provide new leads for creating a vaccine to protect people from HIV infections. Read More »

Drug-resistant malaria extends to Africa

Scientists with the National Institute of Allergy and Infectious Diseases, a branch of the National Institutes of Health, recently discovered that drug-resistant malaria parasites have the ability to spread via mosquito species in Africa. Read More »

Researchers develop protein to reduce HIV reservoir

Researchers from the National Institutes of Health (NIH) recently developed a protein that depletes HIV reservoirs by provoking resting immune cells that have HIV infections and helping along their destruction. Read More »

Novel aerosol vaccine for TB shows promise

A team of researchers has utilized funding from the National Institute of Allergy and Infectious Diseases (NIAID), a branch of the National Institutes of Health (NIH), to create an investigational aerosol vaccine to protect people against tuberculosis (TB). Read More »

Novel anti-Ebola drug may safeguard non-human primates

The results showed that GS-5734 is the first small-molecule antiviral agent that shows robust therapeutic efficacy within monkey subjects infected with Ebola. Read More »

University of Maryland launches HIV vaccine trial

Researchers from the University of Maryland’s Institute of Human Virology in Baltimore recently launched clinical trials for an HIV vaccine candidate. Read More »

HIV therapies without Efavirenz proven effective

Drug combinations built around Efavirenz are often the first treatments recommended when patients are diagnosed with HIV. Read More »

FilmArray Meningitis/Encephalitis Panel receives FDA clearance

BioMerieux, a global leader in vitro diagnostics, recently announced that its molecular biology affiliate, BioFire Diagnostics, has received a de novo clearance from the U.S. Food and Drug Administration (FDA) for the FilmArray Meningitis/Encephalitis (ME) Panel. Read More »

Antiviral compound protects against Ebola in nonhuman primates

Recent research has revealed an antiviral compound that protects non-human primates from contracting the Ebola virus infection. Read More »

HHS unit sponsoring development of drug for severe flu cases

The U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) is sponsoring a drug being developed to treat patients hospitalized with severe cases of influenza. the Biomedical Advanced Research and Development Authority (BARDA) said this week. Read More »

Researchers develop test to detect virtually any virus

A new test that can detect virtually any virus that could infect any human or animal has been developed at Washington University School of Medicine in St. Louis. Read More »

Soft palate plays important role in transmissible influenza viruses

Scientists from the National Institutes of Health (NIH) recently identified the role that the soft palate has in the way influenza viruses transmit from person to person. Read More »

University of Rochester receives funding for HIV vaccine development

University of Rochester School of Medicine and Dentistry researchers specializing in infectious diseases recently received $3.1 million to discover new methods of developing HIV vaccines. Read More »

NIH funds training for junior medical faculty in Africa

The National Institutes of Health (NIH) recently awarded approximately $36.5 million over the next five years to promote junior faculty training in research careers at academic institutions in Africa. Read More »

Ebola drug ZMapp gains fast-track status from the FDA

LeafBio Inc.,  the commercial arm of Mapp Biopharmaceutical Inc., recently announced that its ZMapp has gained fast-track status designation from the U.S. Food and Drug Administration (FDA) as a potential treatment for Ebola. Read More »

Johns Hopkins team improves protective wear for health workers

The Johns Hopkins University's new personal protective suit for health care workers in Ebola outbreaks was recognized this month as one of 10 finalists in the Social Good category of Fast Company's 2015 Innovation by Design Awards. Read More »